Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
MHLW Pushes Boosted Launch Premiums, Slew of Other Pricing Steps to Reward Innovation
To read the full story
Related Article
- Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap
December 21, 2023
- Gist of FY2024 Drug Pricing Reform
December 20, 2023
- Chuikyo Agrees to Scrap Company Indicators to Rank PMP-Eligible Firms
December 14, 2023
- Pharma Industry Backs MHLW Proposal to Scrap PMP Indicators: Chuikyo Hearing
December 7, 2023
- MHLW Proposes Tightening 40% Entry Pricing for New Oral Generics
November 30, 2023
- No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
November 30, 2023
- No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo
November 24, 2023
- MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
- Chuikyo Reps Want More Data from Industry to Review Launch Premiums
July 13, 2023
REGULATORY
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
- MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
- Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…